Servier Brazil

Servier Brazil company information, Employees & Contact Information

Explore related pages

Related company profiles:

We are an international pharmaceutical company, governed by a non-profit foundation based in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4,152 billion euros in 2017, we have a workforce of 21,600 employees worldwide. Totally independent, we reinvest 25% of our revenues (excluding generic drugs) in R&D and use all our profits for development. Corporate growth is driven by our constant pursuit of innovation in 5 areas of excellence: cardiovascular disease, immuno-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as our activities in high quality generic drugs. We currently have 35 candidate drug molecules, including 22 new molecular entities at various stages of clinical development. Our priorities are pathologies with high medical needs within our areas of expertise. To report an adverse reaction with one of our products, please visit our website servier.com.br

Company Details

Employees
17
Founded
-
Address
4211 Estrada Dos Bandeirantes,, Rio De Janeiro,rio De Janeiro 22775-113,brazil
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Rio de Janeiro, Rio de Janeiro
Looking for a particular Servier Brazil employee's phone or email?

Servier Brazil Questions

News

Integrated annual report 2023/2024 - Servier

Integrated annual report 2023/2024 Servier

European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU - PR Newswire

European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU PR Newswire

Servier delivers strong results in 2023/2024 and outpaces its trajectory to 2030 - Servier

Servier delivers strong results in 2023/2024 and outpaces its trajectory to 2030 Servier

Servier and Black Diamond Therapeutics Announce Global - GlobeNewswire

Servier and Black Diamond Therapeutics Announce Global GlobeNewswire

Servier and Google Cloud Expand Partnership on using Data and AI - PR Newswire

Servier and Google Cloud Expand Partnership on using Data and AI PR Newswire

World Diabetes Day: awareness-raising and education at the heart of our subsidiaries’ commitment - Servier

World Diabetes Day: awareness-raising and education at the heart of our subsidiaries’ commitment Servier

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide - PR Newswire

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide PR Newswire

Protecting patients from counterfeit medicines - Servier

Protecting patients from counterfeit medicines Servier

Servier to Present Data on IDH-mutant Glioma at the 2024 Society for Neuro-Oncology (SNO) Congress - PR Newswire

Servier to Present Data on IDH-mutant Glioma at the 2024 Society for Neuro-Oncology (SNO) Congress PR Newswire

Servier, buoyed by high-performance R&D, confirms its 2025 trajectory to achieve its 2030 ambition - Servier

Servier, buoyed by high-performance R&D, confirms its 2025 trajectory to achieve its 2030 ambition Servier

Servier's VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma - PR Newswire

Servier's VORANIGO® (vorasidenib) Tablets Receives FDA Approval as First Targeted Therapy for Grade 2 IDH-mutant Glioma PR Newswire

Fostering a healthy environment - Servier

Fostering a healthy environment Servier

Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma - PR Newswire

Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma PR Newswire

Servier full year 2021/22 results - Servier

Servier full year 2021/22 results Servier

Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI) - PR Newswire

Servier's Pivotal Phase 3 INDIGO Trial Investigating vorasidenib in IDH-Mutant Low-Grade Glioma Meets Primary Endpoint of Progression-Free Survival (PFS) and Key Secondary Endpoint of Time to Next Intervention (TTNI) PR Newswire

Servier committed to energy transition - Servier

Servier committed to energy transition Servier

Servier Completes the Acquisition of Symphogen - PR Newswire

Servier Completes the Acquisition of Symphogen PR Newswire

Servier unveils its 2030 ambition and reveals a new visual identity - Servier

Servier unveils its 2030 ambition and reveals a new visual identity Servier

European Sustainable Development Week - Servier

European Sustainable Development Week Servier

World Cancer Day: Servier, committed to fight cancer - Servier

World Cancer Day: Servier, committed to fight cancer Servier

Servier Completes Acquisition of Agios Pharmaceuticals' Oncology Business - PR Newswire

Servier Completes Acquisition of Agios Pharmaceuticals' Oncology Business PR Newswire

World Environment Day: Servier more committed than ever! - Servier

World Environment Day: Servier more committed than ever! Servier

Servier to Acquire Agios Pharmaceuticals' Oncology Business - PR Newswire

Servier to Acquire Agios Pharmaceuticals' Oncology Business PR Newswire

Servier and Nymirum Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics - PR Newswire

Servier and Nymirum Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics PR Newswire

“CVD patient journey 2020”: a global market research for and with patients affected by chronic venous diseases - Servier

“CVD patient journey 2020”: a global market research for and with patients affected by chronic venous diseases Servier

Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium - Business Wire

Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium Business Wire

FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma - PR Newswire

FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma PR Newswire

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant